Lead Product(s) : Idecabtagene Vicleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Bristol Myers Squibb
Deal Size : $286.0 million
Deal Type : Acquisition
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
Details : Through the acquisition, BMS will gain full control of Abecma (idecabtagene vicleucel), which is indicated for the treatment of relapsed/refractory multiple myeloma.
Product Name : Abecma
Product Type : Cell and Gene therapy
Upfront Cash : $286.0 million
March 10, 2025
Lead Product(s) : Idecabtagene Vicleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Bristol Myers Squibb
Deal Size : $286.0 million
Deal Type : Acquisition
Lead Product(s) : Idecabtagene Vicleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Regeneron Forms Cell Medicines with Acquisition Of 2seventy Bio
Details : Regeneron will have full development and commercialization rights to its pipeline of investigational immune cell therapies, including Abecma (idecabtagene vicleucel).
Product Name : Abecma
Product Type : Cell and Gene therapy
Upfront Cash : $5.0 million
January 30, 2024
Lead Product(s) : Idecabtagene Vicleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia
Details : SC-DARIC33 is a investigational drug-regulated CAR T cell (DARIC) Therapy and T cells activater, which is investigated for the treatment for Acute Myeloid Leukemia.
Product Name : SC-DARIC33
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 14, 2023
Lead Product(s) : Idecabtagene Vicleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Goldman Sachs & Co
Deal Size : $125.0 million
Deal Type : Public Offering
2Seventy Bio Announces Pricing of Upsized Public Offering of Common Stock
Details : The net proceeds will be used for the advancement of the KarMMa trials to support the use of Abecma (idecabtagene vicleucel) in earlier lines of therapy and commercial activities in support of Abecma.
Product Name : Abecma
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 28, 2023
Lead Product(s) : Idecabtagene Vicleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Goldman Sachs & Co
Deal Size : $125.0 million
Deal Type : Public Offering
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : JW Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : The initial focus of the collaboration is 2seventy bio’s MAGE-A4 TCR program in solid tumors which is being developed as part of a collaboration with Regeneron. MAGE-A4 is a member of the MAGE family of cancer-testis antigens expressed in a number of s...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 27, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : JW Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Idecabtagene Vicleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abecma (idecabtagene vicleucel) is B-cell maturation antigen directed CAR-T cell immunotherapy approved in U.S. for treatment of adult patients with multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent.
Product Name : Abecma
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : Idecabtagene Vicleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting
Details : The safety profile of bb21217 is consistent with known toxicities of BCMA CAR T cell therapies, with low rates of Grade ?3 Cytokine Release Syndrome (CRS) and neurotoxicity.
Product Name : BB21217
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 13, 2021
Lead Product(s) : Idecabtagene Vicleucel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
2seventy bio Completes Spin Transaction and Launches Innovative Immuno-oncology Cell Therapy Company
Details : ABECMA (idecabtagene vicleucel), a first-in-class, B-cell maturation antigen (BCMA)-directed CAR T cell immunotherapy approved in the U.S. for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of ...
Product Name : Abecma
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 11, 2021
Lead Product(s) : Idecabtagene Vicleucel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable